Phio Pharmaceuticals Corp. Income Statement
PHIO|7 years of annual SEC 10-K data (FY2012-FY2020)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Phio Pharmaceuticals Corp. reported $21,000 in revenue and $9M in net loss for FY2020. Revenue has declined at a 17.4% compound annual rate over the past 8 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | $21.0K | $138.0K | $15.0K | $19.0K | $34.0K | $97.0K | $97.0K |
| SG&A Expense | $4.7M | $3.2M | $4.0M | $3.6M | $3.3M | $2.6M | $6.1M |
| R&D Expense | $4.3M | $4.3M | $5.4M | $5.4M | $6.9M | $10.5M | $6.6M |
| Operating Income | -$9.0M | -$7.4M | -$14.1M | -$9.0M | -$10.2M | -$13.0M | -$12.8M |
| Interest Expense | - | - | - | - | - | -$30.0K | $598.0K |
| Income Tax | $0 | $0 | -$1.6M | -$1.6M | $0 | - | - |
| Net Income | -$8.9M | -$7.4M | -$12.5M | -$9.0M | -$10.2M | -$89.0K | -$89.0K |
| EPS (Diluted) | -$19.33 | -$57.46 | -$5.52 | -$16.41 | -$2.10 | -$5.62 | -$0.28 |
| Shares Outstanding | 669.4K | 342.6K | 2.4M | 1.3M | 6.5M | 5.3M | 100.4M |
| Operating Margin | -42795.2% | -5336.2% | -93746.7% | -47447.4% | -30108.8% | -13376.3% | -13164.9% |
| Profit Margin | -42419.0% | -5333.3% | -83013.3% | -47336.8% | -30067.6% | -91.8% | -91.8% |